Prior authorization: indication and dosing verification

Prior authorization may be required. Confirm the clinical indication (for example, adjuvant stage III colon cancer) and that dosing and regimen match FDA labeling or published guideline-supported regimens before submission.

• Verify indication and planned regimen (e.g., Eloxatin 85 mg/m2 IV over 120 minutes with leucovorin and 5-FU per labeling for adjuvant/colorectal regimens).
• Confirm cycle length, dose reductions, and duration (e.g., up to 12 cycles for adjuvant stage III colon cancer; continue until progression or unacceptable toxicity for advanced disease).

Prior authorization for systemic oxaliplatin regimens

Prior authorization may be required for systemic oxaliplatin regimens used in combination (e.g., GEMOX for pancreatic, ovarian, or testicular salvage regimens). Document the specific indication, prior lines of therapy, and performance status as applicable.

• Provide documentation of prior therapies and response (e.g., prior platinum exposure, prior salvage regimens).
• State performance status when guidelines recommend use only for patients with good performance status (NCCN guidance).

No explicit prior authorization codes listed

No explicit prior authorization billing codes are listed in this Clinical Policy Bulletin. Use the payer’s prior authorization tool/process and reference appropriate HCPCS/CPT codes when submitting a request.

• HCPCS: J9263 (oxaliplatin, 0.5 mg) — include when selection criteria are met.
• Chemotherapy administration CPT range: 96401–96450 and related Q-codes (Q0083–Q0085) as applicable.

Prior authorization and plan provisions

Refer to the member’s plan provisions and the Aetna Clinical Policy Bulletin for specific prior authorization requirements; this bulletin provides clinical criteria but is not a guarantee of coverage.

• Policies and benefits (including medical necessity rules) remain subject to the member’s specific plan terms.
• Clinical Policy Bulletins are a partial description of plan benefits and do not constitute a contract.

Denial risk for non-adherent dosing or missing allergy documentation

Incomplete or non-conforming documentation and dosing that contradicts FDA labeling or established regimen schedules may result in denial. Missing allergy/anaphylaxis precautions documentation is also a denial risk.

• Document allergy history and plan for management of anaphylactic reactions (epinephrine, corticosteroids, antihistamines available).
• Ensure dose and schedule submitted match FDA labeling or accepted guideline regimens; note any justified deviations and supporting rationale.

Step therapy not specified

No step therapy algorithm or mandatory sequencing rules are specified in this excerpt. Use guideline-based sequencing where applicable and document rationale when deviating from common sequences.

• Although step therapy is not specified here, NCCN guidance informs sequencing decisions for indications such as pancreatic cancer and testicular cancer.
• Document prior lines of therapy when requesting later-line or salvage use (e.g., GEMOX after prior platinum-based regimens).

Sequencing note (informational)

Informational: guideline sources note oxaliplatin can be used as an alternative or subsequent therapy in certain settings (e.g., palliative testicular cancer after first-line salvage therapy; GEMOX or oxaliplatin combinations for pancreatic adenocarcinoma in patients with good performance status).

• NCCN supports oxaliplatin combinations for locally advanced or metastatic pancreatic adenocarcinoma and as subsequent therapy when prior fluoropyrimidine-based chemotherapy has not been given.
• Oxaliplatin may be an alternative in palliative testicular cancer after specified salvage regimens.

Regimen and dosing documentation

Provide regimen, dosing, and supportive documentation with prior authorization submissions: diagnosis, tumor stage, prior therapies, rationale for oxaliplatin use, planned cycle length, dose adjustments, and monitoring plan.

• Include tumor histology, stage, and relevant biomarker status when available (e.g., CPS for gastric cancer analyses).
• Specify planned oxaliplatin dosing (mg/m2), infusion duration, companion agents (5-FU, leucovorin, capecitabine, gemcitabine, gemcitabine schedules), and total planned cycles.

Trial documentation and safety reporting

For investigational approaches or clinical trials (for example, PIPAC‑OX or other investigational intra‑peritoneal delivery), include protocol details, Clavien‑Dindo and CTCAE safety assessments, pharmacokinetic analyses, and trial outcomes when available. Experimental/Investigational uses may be denied.

• Provide trial phase, dose-escalation schema, prior outcomes (OS, PFS, ORR), safety data (TRAEs), and PK methods when claiming medical necessity based on clinical-study evidence.
• Document whether use is within an IRB‑approved trial and include protocol and informed consent references.

Suggested supporting documentation

Suggested supporting documentation: prior therapy history, objective response to prior regimens, duration of response, performance status, labs (CBC, LFTs), and any toxicity history that affects dosing. Include subgroup or biomarker results when relevant.

• Report OS, PFS, ORR, and treatment‑related adverse events from prior lines when citing evidence for coverage.
• Include biomarker subgroup data if used to justify regimen selection (e.g., CPS ≥1 for PD‑1 plus oxaliplatin benefit signals).